Brand-name drug
Rexulti price, strengths & recalls
Brand of brexpiprazole (generic)
Pharmacies pay $1,484.71 for 30 tablets of Rexulti 0.25 mg tablet this week, and from $1,484.48 to $1,486.84 across its 6 priced strengths and forms. Its official label last changed on May 28, 2026.
Medicare price 2028Brand- Fair cash price
- $1,717.92
- Strengths
- 6
- Makers
- 1
- Updated
- Nov 11
Rexulti price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 0.25 mg tablet Brand | $49.49 | $1,484.71 / 30 tablets |
| 0.5 mg tablet Brand | $49.48 | $1,484.48 / 30 tablets |
| 1 mg tablet Brand | $49.56 | $1,486.84 / 30 tablets |
| 2 mg tablet Brand | $49.52 | $1,485.74 / 30 tablets |
| 3 mg tablet Brand | $49.49 | $1,484.72 / 30 tablets |
| 4 mg tablet Brand | $49.55 | $1,486.42 / 30 tablets |
The lowest cost per tablet is 0.5 mg tablet at $49.48. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.
Rexulti vs generic brexpiprazole
There is no generic version of Rexulti on the market yet. Its last listed patent or exclusivity runs to April 12, 2033 - generics often follow, though court cases and settlements can move the date either way.
GenericBrexpiprazole pricesMedicare negotiated price
Rexulti was selected for Medicare price negotiation. Its negotiated price takes effect on January 1, 2028; the price itself is published by the end of November 2026.
What this means for patients
- The negotiated price is what Medicare Part D plans pay for the drug - not your price at the counter.
- What you pay depends on your plan's copay or coinsurance and where you are in the year. Coinsurance (a percentage) falls with the price; a flat copay may not change at all.
- Out-of-pocket costs for Part D drugs are capped each year ($2,100 in 2026), whatever the drug.
- If you don't have Medicare, the negotiated price doesn't apply to you - check the fair cash price above instead.
Supply status: shortages & recalls
What people paid for Rexulti
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use REXULTI safely and effectively. See full prescribing information for REXULTI. REXULTI® (brexpiprazole) tablets, for oral use Initial U.S. Approval: 2015
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDAL THOUGHTS AND BEHAVIORS
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDAL THOUGHTS AND BEHAVIORS
See full prescribing information for complete boxed warning.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at increased risk of death. REXULTI is not approved for the treatment of patients with dementia-related psychosis without agitation associated with dementia due to Alzheimer's disease. (5.1)
Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors. Safety and effectiveness of REXULTI have not been established in pediatric patients with MDD. (5.2, 8.4)
Increased Mortality in Elderly Patients with Dementia-Related Psychosis
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. REXULTI is not approved for the treatment of patients with dementia-related psychosis without agitation associated with dementia due to Alzheimer's disease [see Warnings and Precautions (5.1)].
Suicidal Thoughts and Behaviors
Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric patients and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.2)]. The safety and effectiveness of REXULTI have not been established in pediatric patients with MDD [see Warnings and Precautions (5.2), Use in Specific Populations (8.4)].
Recent major changes (as listed on the label)
Warnings and Precautions (5.6) | 4/2026 |
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA205422 · Otsuka
- First approved
- July 10, 2015 (11 years ago)
- Latest approved change
- April 30, 2026
- Approved label
- PDF, May 5, 2026
- Generic makers
- None on the market
- Last patent listed
- April 12, 2033
- Exclusivity ends
- May 9, 2028
Patent dates are what the maker lists with FDA. Generic launch dates are often set by court rulings or settlements instead. Upcoming generics.
Rexulti questions
How much does rexulti cost without insurance?
Pharmacies pay about $1,484.71 for 30 tablets of rexulti 0.25 mg tablet ($49.49 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $1,717.92. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is there a generic for Rexulti?
Yes: brexpiprazole. Compare brexpiprazole prices.
Is rexulti in shortage?
No shortage is reported for rexulti right now. We check the national shortage list every day.
Has rexulti been recalled?
No recalls are on record for rexulti.
When did the rexulti label last change?
The official label was last updated on May 28, 2026 (version 26). See what changed.
Does Medicare have a negotiated price for Rexulti?
Yes - Rexulti was selected and its negotiated price starts January 1, 2028.
Talk about rexulti
No comments yet. Questions, tips, what worked for you - start the conversation.